Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Jasper Therapeutics, Inc.JSPR · Entity 7588 | See Remarks | March 21, 2022 | March 23, 2022 |
| NextCure, Inc.NXTC · Entity 7461 | Chief Medical Officer | July 14, 2020 | July 16, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Jasper Therapeutics, Inc.
Report date March 21, 2022 · Filed March 23, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.54 · Expires 2032-03-21 | Direct | 7,500 |
Reported balance
After 2022-03-21 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-03-21 · Grant · Acquired 7,500 · Balance 7,500 F1: 1/4th of the shares subject to the option shall vest on December 7, 2022, and 1/48th of the shares subject to the option shall vest following each one-month period thereafter, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive. |
Filing footnotes · ownership attribution and instrument terms
F1: 1/4th of the shares subject to the option shall vest on December 7, 2022, and 1/48th of the shares subject to the option shall vest following each one-month period thereafter, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive.
NextCure, Inc.
Report date July 14, 2020 · Filed July 16, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 49,011 |
Reported balance
After 2020-07-14 transaction · row 1
1 source rowRow 1 · 2020-07-14 · Exercise / conversion · Acquired 27,229 · Balance 49,011 |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.77 · Expires 2028-08-27 | Direct | 38,119 |
Reported balance
After 2020-07-14 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-07-14 · Exercise / conversion · Disposed 27,229 · Balance 38,119 F1: One fourth of the option vested on April 2, 2019. The remainder vests in 36 monthly installments beginning on May 2, 2019. |
Filing footnotes · ownership attribution and instrument terms
F1: One fourth of the option vested on April 2, 2019. The remainder vests in 36 monthly installments beginning on May 2, 2019.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 21, 2022 Filed Mar 23, 2022 18:04 UTC | Jasper Therapeutics, Inc. JSPR · Entity 7588 | GrantStock Option (right to buy) · Derivative | 7,500 | $0.00 Strike: $3.54 | $0.00 |
DisclosureSEC source: 0001213900-22-014568 · ownership.xml · derivative · entry 1 Heller Kevin N. · CIK 0001775716 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Voting Common Stock · 7,500 shares Expires 2032-03-21 F1 · derivative.exercise_date: 1/4th of the shares subject to the option shall vest on December 7, 2022, and 1/48th of the shares subject to the option shall vest following each one-month period thereafter, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive. Read SEC document |
| July 14, 2020 Filed Jul 16, 2020 20:51 UTC | NextCure, Inc. NXTC · Entity 7461 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 27,229 | $0.00 Strike: $1.77 | $0.00 |
DisclosureSEC source: 0001123292-20-000983 · edgar.xml · derivative · entry 2 Heller Kevin N. · CIK 0001775716 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,119 Underlying: Common Stock · 27,229 shares Expires 2028-08-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: One fourth of the option vested on April 2, 2019. The remainder vests in 36 monthly installments beginning on May 2, 2019. Read SEC document |
| July 14, 2020 Filed Jul 16, 2020 20:51 UTC | NextCure, Inc. NXTC · Entity 7461 | Exercise / conversionCommon Stock | 27,229 | $1.77 | $48,195.33 |
DisclosureSEC source: 0001123292-20-000983 · edgar.xml · nonDerivative · entry 1 Heller Kevin N. · CIK 0001775716 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,011 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 21:37 UTC | NextCure, Inc. NXTC · Entity 7461 | GrantEmployee Stock Option (Right to Buy) · Derivative | 100,050 | $0.00 Strike: $41.76 | $0.00 |
DisclosureSEC source: 0001123292-20-000461 · edgar.xml · derivative · entry 1 Heller Kevin N. · CIK 0001775716 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,050 Underlying: Common Stock · 100,050 shares Expires 2030-02-27 F1 · derivative.exercise_date: One fourth of the option vests on February 28, 2021. The remainder vests in 36 monthly installments beginning on March 28, 2021. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.